Expiration date: 07/2026

Active substance: emoxypine (Ethylmethylhydroxypyridine succinate)

Pharmachologic effect:  antioxidant

Pharmacodynamics

MEXIDOL® is an inhibitor of free-radical processes, membrane protectors, have anti, stressprotektivnym, neuroprotective, anticonvulsant and anxiolytic effects. The drug increases the body's resistance to the effects of various damaging factors (shock, hypoxia and ischemia, cerebrovascular accident, alcohol intoxication and antipsychotic drugs (neuroleptics).

The mechanism of action is due to its antioxidant Meksidola®, antihypoxic and membrane action. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the ratio of lipid-protein, reduces the viscosity of the membrane increases its fluidity.

MEXIDOL® modulates the activity of membrane-bound enzymes (kaltsiynezavisimoy phosphodiesterase, adenylate cyclase, acetylcholinesterase) receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, it helps to preserve the structural and functional organization of biological membranes, transport of neurotransmitters and improve synaptic transmission.

MEXIDOL® content increases brain dopamine. It is a compensatory increase in the activation of aerobic glycolysis and decreased inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with increasing the content of ATP and creatine phosphate, activation energosinteziruyuschih functions of mitochondria, stabilizing cell membranes. The drug improves metabolism and blood flow to the brain, improves microcirculation and blood rheology, reduces platelet aggregation. It stabilizes the membrane structure of blood cells (erythrocytes and platelets) for hemolysis. It has hypolipidemic effect, reduces total cholesterol and LDL.

Anti-stress effect is the normalization of post-stress behavior, somatovegetativnyh disorders, sleep- wake cycles restoring disturbed learning and memory processes, and reducing the degenerative morphological changes in different brain structures.

MEXIDOL® has a strong detoxifying effect in withdrawal syndrome. It eliminates neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral, autonomic functions, and is able to remove the cognitive impairment caused by prolonged use of ethanol and its abolition.

Influenced Meksidola® enhanced tranquilizing effect, antipsychotic, antidepressant, hypnotic and anticonvulsant agents, allowing them to reduce the dose and reduce side effects.

MEXIDOL® improves the functional state of the ischemic myocardium. In the context of coronary heart disease increases collateral blood supply to ischemic myocardium, helps to preserve the integrity of kardimiotsitov and maintain their functional activity. Effectively restores myocardial contractility with reversible cardiac dysfunction.

Pharmacokinetics

Quickly absorbed by ingestion. When administered in doses of 400-500 mg Cmax of 3.5-4 mcg / mL. Quickly spread to organs and tissues. The average retention time of the drug in the body by ingestion - 4.9-5.2 hours.

It is metabolized in the liver by glyukuronkonyugirovaniya. Identified metabolites 5: 3-hydroxypyridine phosphate - formed in the liver and with the participation of ALP splits into phosphoric acid and 3-oxy-pyridin; 2nd metabolite - a pharmacologically active and is formed in large quantities and is found in the urine at the 1.2 th day after administration; 3rd - displayed in large amounts in the urine; 4 th and 5 th - glyukuronkonyugaty.

T1 / 2 when administered -. H 2-2,6 rapidly excreted in the urine primarily as metabolites and small amounts unchanged. The most extensively excreted within the first 4 hours after ingestion. Performance in the urine excretion of unchanged drug and metabolites have individual variability.

Testimony

• effects of stroke, including after a transient ischemic attack, in phase subcompensation as prevention courses;
  
• mild traumatic brain injury, the effects of traumatic brain injury;
  
• encephalopathies of various origins (dyscirculatory, dysmetabolic, post-traumatic, mixed);
  
• vegetative dystonia syndrome;
  
• mild cognitive disorders of atherosclerotic;
  
• anxiety disorders in neurotic and neurosis-like states;
  
• Coronary heart disease (in the complex therapy);
  
• Relief of abstinence syndrome in alcoholism with a predominance of neurosis and vegetative-vascular disorders, postabstinentnom disorder;
  
• state after acute intoxication antipsychotics;
  
• asthenic conditions;
  
• prevention of systemic diseases under the influence of extreme factors and loads;
  
• exposure to extreme (stress) factors.
  

Contraindications

• Increased individual sensitivity to the drug;
  
• acute renal failure;
  
• acute liver failure.
  

Due to insufficient knowledge of the drug - the children's age, pregnancy, breastfeeding.

Side effects

Perhaps the appearance of individual adverse reactions or dyspeptic dyspeptic nature of allergic reactions.

Interaction

MEXIDOL® combined with all drugs used for the treatment of systemic diseases.

It enhances the effect of the benzodiazepine drugs, antidepressants, anxiolytics, anticonvulsants, antiparkinsonian agents. It reduces the toxic effects of ethanol.

Dosing and Administration

Inside, in the 125-250 mg 3 times a day; the maximum daily dose - 800 mg (see Table 6.).

Duration of treatment - 2-6 weeks; for the relief of alcohol withdrawal - 5-7 days. Treatment stopped gradually, reducing the dose for 2-3 days.

The initial dose - 125-250 mg (1-2 tablets.) 1-2 times a day with a gradual increase until the therapeutic effect; the maximum daily dose - 800 mg (see Table 6.).

Duration of therapy in patients with coronary artery disease - at least 1,5-2 months. Repeated courses (on doctor's advice), it is desirable to carry out in the spring and autumn periods.

Overdose

Symptoms may develop drowsiness.

Special instructions

Effects on ability to drive or engage in other potentially hazardous activities. During the period of treatment must be careful when driving and occupation of other potentially hazardous activities that require high concentration and psychomotor speed reactions.

Release Form

Tablets, film-coated, 125 mg. According to Table 10. in blisters made of PVC foil and aluminum foil. 1, 2, 3, 4, 5, the contour of cellular packages in a stack of cardboard.

Storage conditions

In a dry, dark place at a temperature no higher than 25 ° C.

Keep out of the reach of children.

Shelf life

3 years. Do not use after the date printed on the packaging

Do not use beyond the expiration date printed on the package.